CORONA Remedies: Reg. 74(5) Certificate for Q1 FY27 Confirms Shares in Demat Form
CORONA Remedies Limited received a certificate for the quarter ended June 30, 2026, confirming that Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, is not applicable. This is due to the company's entire shareholding being in demat form, with no rematerialisation requests received.
This is a standard regulatory filing confirming the dematerialized status of shares, which is a routine process and does not represent a material event for the company.
The announcement is a routine compliance filing related to shareholding status and does not contain any information that would positively or negatively impact the company's valuation or operations.
CORONA Remedies Limited has submitted a certificate pursuant to Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018, for the first quarter ended June 30, 2026. The certificate was received from M/s. Bigshare Services Private Limited, the Company's Registrar to Issue and Share Transfer Agent.
Bigshare Services Private Limited confirmed that Regulation 74(5) is not applicable to CORONA Remedies Limited for the quarter ended June 30, 2026. This is because the entire holding of the company's shares is in demat form. Furthermore, no requests were received from any shareholders for the rematerialisation or dematerialisation of shares during the period from March 31, 2026, to June 30, 2026.
The company has informed BSE Limited and the National Stock Exchange of India Limited, as well as depositories NSDL and CDSL, to take note of this confirmation for their records.
What to do with a filing like this
CORONA Remedies Limited filed this with the NSE as a statutory disclosure, categorised under sebi compliance filings. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by CORONA Remedies Limited. Read the original for the full detail.